Incorporating biomarkers into clinical trial designs: points to consider.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Feasibility, safety, and adequacy of research biopsies for cancer clinical trials at an academic medical center.PloS one · 2019
   Trial
2. Artificial intelligence fusion for predicting survival of rectal cancer patients using immunohistochemical expression of Ras homolog family member B in biopsy.Exploration of targeted anti-tumor therapy · 2023
   Article
3. Radiogenomics is the future of treatment response assessment in clinical oncology.Medical physics · 2018
   Article
4. Drugs' development in acute heart failure: what went wrong?Heart failure reviews · 2018
   Review
5. Advances in the design of nanomaterial-based electrochemical affinity and enzymatic biosensors for metabolic biomarkers: A review.Mikrochimica acta · 2018
   Review
6. Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.Journal of personalized medicine · 2017
   Review
7. Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.PloS one · 2016
   Review
8. Creative trial design in RA: optimizing patient outcomes.Nature reviews. Rheumatology · 2013
   Article
9. The Importance of Biopsy in the Era of Molecular Medicine.Cancer journal (Sudbury, Mass.)
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as